What is the new FDA-approved pill designed to slash cholesterol levels?

The Food and Drug Administration has approved a new daily pill, Lipfendra, to lower cholesterol levels. Developed by Merck, the drug works by inhibiting the PCSK9 protein. This mechanism is notable because, until now, such treatment was only available through regular injections. Clinical trials demonstrate that Lipfendra reduces LDL cholesterol by 60 percent, which is a significant improvement over the 30 to 50 percent reduction seen with most statins.

Patients at high risk for heart attacks or strokes often require their LDL levels to fall below 70 or 55. Lipfendra offers a non-invasive option for those who do not respond well to statins or prefer to avoid needles. Statins can cause muscle pain, weakness, and other gastrointestinal issues for some patients, whereas Lipfendra clinical trials showed side effects comparable to a placebo. This makes the drug an alternative for those seeking potent lipid management.

Merck has priced the pill at 315 dollars for a 30-day supply, which is less than the 500 to 600 dollar monthly cost associated with current injectable treatments. Experts indicate the medication will become available within weeks. Patients should note that the drug must be taken in the morning on an empty stomach. Cardiologists see this as a practical shift in heart health management, particularly for patients who have avoided injectables.

While the drug is newly approved, Merck is conducting further studies to confirm its long-term impact on preventing heart attacks and strokes. Previous research on injectable PCSK9 inhibitors showed a 20 percent reduction in cardiovascular deaths for high-risk individuals. This approval marks a shift in how medical professionals manage high cholesterol in high-risk populations.